$ACAD
ACADIA PHARMACEUTICALS INC

2012 Q4 Form 10-Q Financial Statement

#000119312512451812 Filed on November 05, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $380.0K $3.478M $584.0K
YoY Change -35.37% 495.55% -74.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.300M $1.500M $1.500M
YoY Change 53.33% 0.0% -6.25%
% of Gross Profit
Research & Development $4.900M $4.400M $4.158M
YoY Change 11.36% 5.82% -16.84%
% of Gross Profit
Depreciation & Amortization $20.00K $30.00K $30.00K
YoY Change -33.33% 0.0% -70.0%
% of Gross Profit
Operating Expenses $7.200M $5.885M $5.677M
YoY Change 22.03% 3.66% -12.66%
Operating Profit -$2.407M -$5.093M
YoY Change -52.74%
Interest Expense $0.00 $5.000K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.800M -$2.400M -$5.100M
YoY Change 28.3% -52.94% 21.43%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.810M -$2.402M -$5.076M
YoY Change 28.49% -52.68% 20.86%
Net Earnings / Revenue -1792.11% -69.06% -869.18%
Basic Earnings Per Share
Diluted Earnings Per Share -$112.0K -$44.53K -$96.59K
COMMON SHARES
Basic Shares Outstanding 56.62M shares 53.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.0M $23.10M $36.20M
YoY Change 248.28% -36.19% 12.42%
Cash & Equivalents $57.90M $8.016M $8.317M
Short-Term Investments $50.07M $15.00M $27.80M
Other Short-Term Assets $600.0K $600.0K $600.0K
YoY Change -33.33% 0.0% -25.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $108.5M $23.69M $36.80M
YoY Change 239.75% -35.64% 5.14%
LONG-TERM ASSETS
Property, Plant & Equipment $42.00K $63.00K $200.0K
YoY Change -72.19% -68.5% -66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $2.000K $100.0K
YoY Change -100.0% -98.0% 0.0%
Total Long-Term Assets $42.00K $65.00K $200.0K
YoY Change -74.55% -67.5% -75.0%
TOTAL ASSETS
Total Short-Term Assets $108.5M $23.69M $36.80M
Total Long-Term Assets $42.00K $65.00K $200.0K
Total Assets $108.6M $23.75M $37.00M
YoY Change 238.14% -35.81% 3.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.375M $1.131M $1.300M
YoY Change -29.85% -13.0% -50.0%
Accrued Expenses $4.139M $4.686M $4.400M
YoY Change 18.12% 6.5% 15.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $5.948M $6.086M $6.400M
YoY Change -3.52% -4.91% -51.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.70M $0.00 $2.500M
YoY Change 580.77% -100.0% -88.99%
Total Long-Term Liabilities $17.70M $0.00 $2.500M
YoY Change 580.77% -100.0% -88.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.948M $6.086M $6.400M
Total Long-Term Liabilities $17.70M $0.00 $2.500M
Total Liabilities $5.948M $6.086M $8.900M
YoY Change -32.04% -31.62% -75.21%
SHAREHOLDERS EQUITY
Retained Earnings -$367.7M -$360.9M
YoY Change 6.01%
Common Stock $7.000K $6.000K
YoY Change 40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $84.98M $17.66M $28.10M
YoY Change
Total Liabilities & Shareholders Equity $108.6M $23.75M $37.00M
YoY Change 238.14% -35.81% 3.35%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income -$6.810M -$2.402M -$5.076M
YoY Change 28.49% -52.68% 20.86%
Depreciation, Depletion And Amortization $20.00K $30.00K $30.00K
YoY Change -33.33% 0.0% -70.0%
Cash From Operating Activities -$6.290M -$5.310M -$4.170M
YoY Change 17.79% 27.34% 65.48%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$35.06M -$2.740M $4.480M
YoY Change -1020.21% -161.16% 52.38%
Cash From Investing Activities -$35.06M -$2.740M $4.480M
YoY Change -1020.21% -161.16% 52.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 91.23M 6.860M -10.00K
YoY Change 101266.67% -68700.0% -103.12%
NET CHANGE
Cash From Operating Activities -6.290M -5.310M -4.170M
Cash From Investing Activities -35.06M -2.740M 4.480M
Cash From Financing Activities 91.23M 6.860M -10.00K
Net Change In Cash 49.88M -1.190M 300.0K
YoY Change -3563.89% -496.67% -59.46%
FREE CASH FLOW
Cash From Operating Activities -$6.290M -$5.310M -$4.170M
Capital Expenditures $0.00
Free Cash Flow -$4.170M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
15000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1175000
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8317000
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
627000
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2000
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
17664000
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.35 shares
CY2011Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.38
CY2011Q1 acad Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
4397904 shares
CY2011Q1 acad Warrants Expiration Month And Year
WarrantsExpirationMonthAndYear
2018-01
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56621575 shares
CY2012Q1 acad Commission Rate
CommissionRate
0.03 pure
CY2012Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3200000
CY2012Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
211000
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
626000
CY2012Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
16292000
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56589443 shares
CY2012Q3 us-gaap Liabilities
Liabilities
6086000
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1131000
CY2012Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
15042000
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
266000
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360910000
CY2012Q3 us-gaap Assets
Assets
23750000
CY2012Q3 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
1000
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23750000
CY2012Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8016000
CY2012Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
22753000
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56589443 shares
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4686000
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6086000
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q3 us-gaap Assets Current
AssetsCurrent
23685000
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63000
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
378564000
CY2012Q3 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
16293000
CY2012Q3 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
3849000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6849000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
901000
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
23362000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
333000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
679000
CY2011Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
24155000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52898659 shares
CY2011Q4 us-gaap Liabilities
Liabilities
8752000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1960000
CY2011Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
24159000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
669000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-346871000
CY2011Q4 us-gaap Assets
Assets
32114000
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
5000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32114000
CY2011Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
32000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6889000
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
1000
CY2011Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
30729000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52898659 shares
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9000
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3504000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6165000
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2587000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
31949000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151000
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
370219000
CY2011Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
24159000
CY2011Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
2492000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-68000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17538000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-728000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13916000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17971000
us-gaap Share Based Compensation
ShareBasedCompensation
1190000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
41982000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Investment Income Net
InvestmentIncomeNet
73000
us-gaap Other Noncash Expense
OtherNoncashExpense
806000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14559000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2165000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-164000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1468000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6132000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-42000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
69000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-157000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
3000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12885000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13847000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
39814000
us-gaap Operating Expenses
OperatingExpenses
19017000
us-gaap Revenues
Revenues
1479000
us-gaap Depreciation
Depreciation
255000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-241000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51963000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9830000 shares
us-gaap Net Income Loss
NetIncomeLoss
-17465000
dei Trading Symbol
TradingSymbol
ACAD
dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001070494
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Operating Income Loss
OperatingIncomeLoss
-14067000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15336000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9526000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2990000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1127000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-829000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6967000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14044000
us-gaap Share Based Compensation
ShareBasedCompensation
1379000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
24883000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap Investment Income Net
InvestmentIncomeNet
28000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4701000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-12000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
28000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-274000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-252000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13893000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6939000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
15609000
us-gaap Operating Expenses
OperatingExpenses
18594000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-252000
us-gaap Revenues
Revenues
4527000
us-gaap Depreciation
Depreciation
88000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
161000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53262000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11502000 shares
us-gaap Net Income Loss
NetIncomeLoss
-14039000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1182000
CY2011Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13900000
CY2011Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12565446 shares
CY2011Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
1.19375
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5093000
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5080000
CY2011Q3 us-gaap Share Based Compensation
ShareBasedCompensation
401000
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2011Q3 us-gaap Investment Income Net
InvestmentIncomeNet
17000
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1519000
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4158000
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
5677000
CY2011Q3 us-gaap Revenues
Revenues
584000
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52800000 shares
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10414000 shares
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-5076000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2407000
CY2012Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6800000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2400000
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
488000
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2012Q3 us-gaap Investment Income Net
InvestmentIncomeNet
5000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1485000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4400000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
5885000
CY2012Q3 us-gaap Revenues
Revenues
3478000
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53911000 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11919000 shares
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2402000
CY2012Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3491500 shares
CY2012Q3 acad Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
7000000

Files In Submission

Name View Source Status
0001193125-12-451812-index-headers.html Edgar Link pending
0001193125-12-451812-index.html Edgar Link pending
0001193125-12-451812.txt Edgar Link pending
0001193125-12-451812-xbrl.zip Edgar Link pending
acad-20120930.xml Edgar Link completed
acad-20120930.xsd Edgar Link pending
acad-20120930_cal.xml Edgar Link unprocessable
acad-20120930_def.xml Edgar Link unprocessable
acad-20120930_lab.xml Edgar Link unprocessable
acad-20120930_pre.xml Edgar Link unprocessable
d410323d10q.htm Edgar Link pending
d410323dex101.htm Edgar Link pending
d410323dex311.htm Edgar Link pending
d410323dex312.htm Edgar Link pending
d410323dex321.htm Edgar Link pending
d410323dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending